Patient FAQ — Advanced Cancer Treatment Approaches

Japan operates under a highly developed healthcare system regulated by the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA). This system includes special legal pathways — such as Advanced Medical Care (Senshin Iryo) and conditional approval frameworks — that allow licensed institutions to make newer medical options available under defined safeguards. Our role is to review the patient's intake information and diagnostic history, organize an appropriate referral path, and help connect the case to a licensed Japanese hospital or specialist clinic that is suited to review it further.

Most Japanese specialized clinics do not accept international patients directly. JapanMedAssist bridges this gap by acting as your official administrative coordinator. Here is how we help you successfully secure treatment:

• Overcoming language barriers: Japanese medical facilities communicate exclusively in Japanese. We handle all official correspondence and provide professional document translation services for your records.
• Complex record preparation: clinics require strict, specific health record formats and preliminary screening protocols. We organize your medical history to meet precise Japanese standards.
• Multi-clinic network: treatment protocols vary widely, and clinics frequently decline cases. We leverage established relationships with multiple facilities to find the best match for your specific diagnosis.
• Expedited registration: Japanese oncology centers can be overwhelmed with inquiries. We present your case as a "ready-to-review" medical case, bypassing administrative delays to fast-track your intake.
• On-site interpretation support: to ensure safety and clear communication during your medical appointments, we provide in-person interpretation services at the clinic when necessary.

As clinics offering advanced immunotherapies generally operate on a strict reservation-only system, online consultations are necessary for doctors to evaluate your condition, answer your questions about proposed therapies, and plan the appropriate treatment. We will schedule consultation (conducted via Zoom or Google Meet) at a timeslot that is appropriate for both the patient and the doctor, considering timezone differences.

To accurately assess your condition, doctors prefer to review as much medical information as possible. If available, please provide:

• Recent imaging scans (CT, MRI, PET-CT, X-rays).
• Blood test data and pathology reports.
• A medical summary, treatment history and/or proposed treatment plan from your current oncologist.
• A list of current medications.

While the purpose of the initial Zoom call is to establish how immune-cell therapy can be integrated into your treatment plan, dedicated second-opinion consultations are available to review your diagnosis and treatment from the perspective of an immune-cell therapy expert. If the patient cannot attend in person, a family member or representative can usually attend on their behalf. Consultations that are primarily for second opinions must be scheduled separately from the initial consultation, as they require a different preparation and review process. Please contact us to discuss your specific situation and schedule a second-opinion consultation if needed.

If a treatment plan is available, review it before the consultation. Write a short list covering your main concerns, current care, timing, and what you hope to understand from the consultation.

Ask about the purpose of the proposed service, available evidence, risks, alternatives, costs, visit requirements, and follow-up responsibilities.

A virtual consultation provides an expert medical case review with a specialist. It does not guarantee clinical eligibility, institutional availability, specific prescriptions, or definitive medical outcomes.

Interpretation support may be coordinated when requested and available. We will confirm the language arrangements before the appointment.

You can upload existing health summaries directly into our secure, encrypted patient workspace. These files are shared safely only with authorized personnel involved in your administrative care coordination. We can also assist with obtaining records from your current care team and securely transferring them to the clinic in Japan.

Documentation guidelines depend on the chosen facility. Submit the available original language versions first, and we will take care of any necessary translation coordination based on their requirements.

Yes. You may provide accessible links and any instructions needed to open protected files. We will obtain the necessary access and share the records securely to the reviewing clinical team.

Submit what is available and identify missing items. The reviewing party will determine if additional diagnostic reports are mandatory before scheduling your appointment.

Our coordinator first checks the request for administrative completeness. An independent clinic then decides whether it can review the case.

Most requests with complete documentation are processed by us within 1-2 working days, and Japanese clinics typically review cases within the same week. However, timing can vary based on the clinic’s schedule and the complexity of the case. We attempt to find a clinic that can review the case as quickly as possible. A virtual second opinion or consultation is typically scheduled within 1 to 7 business days following clinic acceptance, depending on physician availability.

You will receive an administrative summary detailing the specialist's guidance. If you decide to proceed with an on-site visit, our office will manage your logistical arrangements, including Japan medical visa support, travel planning, and records handling.

Yes. Upon intake approval, our office provides continuous support by managing administrative communications and secure data updates between you and the Japanese facility.

Japan Medical Assist specializes in non-clinical Japan medical travel support. Our administrative scope includes secure records management, doctor appointment scheduling, professional interpreter coordination, and travel planning for confirmed medical itineraries.

Only licensed clinicians at independent clinics or hospitals provide diagnoses, clinical advice, eligibility decisions, and care recommendations.

Our role is to identify suitable options within our Japanese provider network. The independent medical center retains absolute autonomy over case reviews and individual patient acceptance.

Every healthcare provider independently appraises your submitted files to determine evaluation feasibility. If a specific center declines the request, we utilize our network to locate alternative medical tourism Japan hospital options.

Yes. Website text and logistical discussions should never replace your current care plan. Always consult your primary local doctor before making clinical choices. Coordinated options do not substitute for ongoing local oncology or chronic care management.

These therapies are applied to treat active cancer as well as to help prevent postoperative recurrence. They can be applied to almost all cancer types (e.g., lung cancer, melanomas, breast cancer, gastrointestinal cancers, glioblastoma, sarcoma, kidney cancer, bladder cancer, stomach cancer, colon cancer, and esophageal cancer, and many others), with the exception of certain blood cancers like specific types of leukemia and T-cell malignant lymphoma. Patients with active or treated brain metastases require careful individual review.

The goal is not necessarily to eradicate every single cancer cell immediately, but to slow tumor growth, strengthen the body's defenses, and allow patients to maintain a high quality of life. The philosophy is to calm the disease and live with it peacefully without provoking it to become aggressively lethal.

Cancer cells create a protective "microenvironment" (a biological shield) that prevents immune cells from attacking them effectively. Furthermore, cancer is a "moving target." Through a process called epithelial-mesenchymal transition, tumor cells can mutate, become invasive, and develop resistance to previous therapies. The treatment strategy aims to adapt to the current state of the disease, breaking this shield while simultaneously boosting immune and stem cells.

Yes. While it varies by individual, there are cases where patients experience significant pain relief due to tumor shrinkage or a reduction in inflammation. Some patients also see a decrease in fluid accumulation (such as pleural effusion or ascites) as a result of the treatment.

Yes. It is highly recommended to combine standard therapies (like chemotherapy, radiation, and surgery) with these advanced options rather than relying on a single treatment. However, careful coordination is required. For example, if a patient is on strong immunotherapy drugs (like PD-L1 inhibitors), a break of at least two weeks is generally required before starting immune-cell therapy to prevent the immune system from becoming dangerously overactive.

• Dendritic Cell (DC) Vaccine: This therapy activates your acquired (adaptive) immunity. It acts like a sniper, using specific cancer markers (antigens) to educate the immune system to recognize, memorize, and specifically attack those cancer cells.
• Activated NK-Cell Therapy: This therapy activates your innate immunity. Natural Killer cells are multiplied and activated in a lab to broadly attack abnormal cells, specifically targeting cancer cells or virus-infected cells that try to hide their markers from the adaptive immune system.

Yes. Because the DC vaccine helps the immune system "memorize" the cancer's profile (much like a standard vaccine memorizes a virus), it is considered highly beneficial for preventing metastasis and relapse. It targets microscopic cancer cells that may remain in the body after surgery.

It is often chosen for cancer prevention, relapse prevention after standard treatments, or for patients who cannot physically endure harsh standard therapies (like heavy chemotherapy) or for whom standard treatments are no longer effective.

For advanced or metastasized cases, a multi-hybrid approach combines the dendritic cell vaccine with a mixture of Natural Killer (NK) cells, NK-like T-cells, and gamma-delta T-cells. This combined approach prevents cancer cells from hiding and attacks the disease from multiple biological angles.

The therapy is built on a triple-reinforcement strategy designed to overcome the limitations of standard DC vaccines:

• Endogenous Adjuvant DC Activation: A patented culture method uses immune adjuvant nucleic acids to significantly enhance anti-tumor cytokine production (like IL-12 and TNF-a) and dramatically improve antigen presentation efficiency.
• Peptiẞ (PeptiẞAntigen): Unlike conventional peptides that are limited to specific HLA types, this uses an HLA-optimized, multi-epitope design that is highly immunogenic and compatible with diverse cancer types.
• NKT Cell Activation via α-GalCer: This component bridges innate and adaptive immunity, causing an immediate secretion of cytokines that helps reset the immunosuppressive environment within the tumor from the very beginning.

If specific actionable mutations are found in the tumor, targeted molecular therapy can be used. For example, testing for a c-KIT mutation is a crucial first step for certain rare tumors. If positive, specialized inhibitors can be highly effective at blocking the cancer's growth mechanism.

• Because cancer cells cannot dilate blood vessels properly, they retain heat and reach much higher temperatures than normal cells when exposed to thermal energy.
• At temperatures of 42.5°C and above, cell death occurs; at 43°C, cancer cell viability drops below 1/10,000 within 200 minutes.
• Heating the tumor safely with an 8 MHz high-frequency device locally warms the tissue to 39-41°C, which activates immune cells (like macrophages and NK cells) and improves the uptake of anticancer drugs into the tumor.

• When cancer cells die from targeted treatments (like radiation therapy or specific drugs), they release "danger signals" such as DAMPs.
• These signals naturally activate dendritic cells, triggering a powerful chain reaction that wakes up the immune system to recognize and attack the cancer systemically.

• A specialized compound (IR-783) selectively accumulates in cancer cells due to their unique transport mechanisms, with minimal impact on normal healthy cells.
• By applying an 810 nm near-infrared laser (which can penetrate deep tissues or be delivered directly via endoscopy for gastrointestinal cancers like stomach, colon, and esophageal), the targeted cancer cells are selectively destroyed.
• This approach can be combined with hyperthermia to increase local tumor blood flow, maximizing the drug's accumulation efficiency in the cancer cells.

• Beselna cream acts as a local "peripheral igniter" by stimulating Toll-like receptor 7 (TLR7) when applied to the epidermis and dermis.
• Because the skin is rich in immune-sensitive cells, applying the cream creates a localized immune response that promotes the maturation and migration of dendritic cells.
• This provides a dual-stimulation effect that perfectly complements the systemic DC vaccine by recruiting more T cells to the specific area and amplifying the overall anti-tumor response.

Complete or partial removal (resection) of the tumor is highly preferred over a simple needle biopsy. Surgery helps extend the patient's lifespan and allows for the collection of a sufficient amount of tumor tissue (usually 2 to 5 grams) needed to create the personalized cancer vaccine. If surgery is not possible, a large core needle biopsy can be considered, but it may not provide enough tissue for optimal vaccine production. In cases where no tumor tissue is available, the clinic can use synthesized peptides to create a multivalent vaccine, though this is generally less effective than using the patient's own tumor antigens.

Yes. Preserved (paraffin-embedded) tumor blocks containing dead cancer cells can be utilized. When injected, these dead cells express irritating molecules that provoke and "wake up" the immune system, training it to target the specific biology of your tumor.

If a patient's own tumor tissue is completely unavailable, the clinic can manufacture a multivalent dendritic cell vaccine using artificial cancer antigens (synthesized peptides). Advanced long-chain peptides (such as WT1 or NY-ESO-1) that cover full protein sequences can be utilized, ensuring the treatment can be matched to almost any patient regardless of whether they have stored tissue.

• Two weeks before administering the DC therapy, a low-dose of cyclophosphamide (Endoxan) is given as a "metronomic therapy".
• The purpose is to selectively suppress immunosuppressive cells in the body, such as Tregs and MDSCs, creating an "immune reset".
• Relieving this immunosuppressive environment allows the DC vaccine to work effectively and induces a stronger, more sustained anti-tumor response.

• Cancer cells thrive by preferentially using glycolysis to produce large amounts of lactate (the Warburg Effect), which drops the pH around the tumor to an acidic 6.0-6.5.
• This severely acidic environment paralyzes T cells and NK cells, while promoting immune-suppressing cells.
• While systemic blood pH cannot be significantly altered by food, maintaining a nutrient-dense, plant-rich diet supports overall immune function and metabolic health.
• Restricting refined carbohydrates is also recommended to suppress growth signals during active cancer growth, though extreme restriction during immunotherapy is avoided to ensure T cells have adequate energy to fight.

• Metformin, typically a diabetes medication, is utilized to activate AMPK, which acts as the cell's energy sensor.
• This activation suppresses cancer cell proliferation, induces cancer cell death (apoptosis), promotes autophagy, and assists in the formation of memory T cells.

Generally, no. Imaging scans (MRI/CT) are typically not performed during the first visit because it is too early to assess treatment dynamics. Instead, your status and treatment progress will be monitored later through follow-up imaging and comprehensive blood tests.

We advise booking travel only after your clinic schedule is finalized and you have reviewed all service fees and travel requirements. On-site appointments are typically scheduled within 1 to 3 weeks post-consultation. Once your schedule is confirmed, we can assist with travel arrangements and provide guidance on accommodations near the clinic.

No, these treatments are strictly outpatient, and the clinics generally do not have inpatient facilities. We can recommend or assist with booking accommodations in clinic's vicinity if needed. However, if a patient is traveling from afar or their overall health condition makes daily commuting difficult, the clinic can introduce you to affiliated hospitals where you can stay.

Depending on treatment plan, the initial phase typically requires coming to Japan for about 7-10 days. During this period, you will visit the clinic every day. The treatment itself usually takes approximately 30 to 60 minutes each day. A dedicated coordinator will assist you during your clinic visits to ensure smooth communication and comfort. Almost all plans require another 7-10 days visit after 2-3 weeks. Alternatively, patients may combine both visits into a single 4-5 week trip.

While the clinic can coordinate records and timing with your local oncologist, any complications or medical emergencies occurring in your home country must be managed locally by your primary medical team.

No. The vast majority of our proposed advanced treatment protocols are outpatient and take 4 to 6 weeks at most, with the option to split therapies into multiple separate visits. Because these travels fall well within the standard 90-day temporary stay limit, a standard short-term visitor stay is sufficient, and a specialized medical stay visa is not required.

• Standard Short-Term Stay: Sufficient for stays up to 90 days, covering the full duration of most cellular and supportive treatment cycles.
• Legal Clarification: This regulatory point has been verified directly with the Ministry of Foreign Affairs of Japan through our legal immigration counsel.

Yes. You may bring a family member or authorized representative to your appointments. We can help coordinate their involvement and ensure they have the necessary information to support you during your visit.

All applicable consultation rates and coordinator fees are disclosed upfront. Because advanced care plans are highly personalized, formal cost estimates are issued only after the clinic reviews the file and provides specific recommendations. Once you receive the clinic's recommendations, we will provide a detailed breakdown of all related fees, including consultation charges, administrative coordination costs, and any anticipated expenses for recommended services. This allows you to make an informed decision about proceeding with the proposed care plan.

Patients may not be eligible if they are taking high-dose steroids, are on strong immunosuppressive therapy, have autoimmune diseases, have a history of organ transplants, or carry viruses that grow within immune cells (such as HIV or HTLV). Additionally, patients whose overall health is too poor (e.g., unable to eat, walk, or travel) might have severely impaired immune systems, making it difficult to achieve the expected treatment outcome.

Chemotherapy can lower your white blood cell count, making it harder to cultivate enough high-quality immune cells from a blood draw. It is often recommended to complete your current round of chemotherapy before starting immune-cell therapy.

Due to the specialized nature of the proposed treatments and the fact that they are provided by independent clinics, insurance coverage is generally not available. We recommend consulting with your insurance provider to understand your specific policy details and any potential for reimbursement. The expenses may be eligible for medical expense tax deductions depending on your country's local tax laws.

Clinical follow-up instructions will originate from licensed medical professionals, and the independent Japanese facility providing your care will remain responsible for tracking progress and issuing medical recommendations.

We will stay in touch with you before, during, and after your visit. Please use the secure client portal or contact your coordinator directly for ongoing account management, document updates, or scheduling help. Our team remains available to facilitate follow-up communication with clinics, bookings, or secondary consultations.

Progress is judged comprehensively. Evaluations typically happen immediately after the first course of treatment and again 3 months later. Progress is measured using:

• Quality of Life (QOL) assessments (monitoring energy, sleep, and symptom reduction).
• Specialized blood tests, such as the T-cell response cytokine test (immunogram).
• Tumor marker levels in the blood.
• Imaging scans (MRI, CT, PET-CT).

Outcomes vary significantly depending on the type, stage, and biology of the cancer, as well as the patient's overall health and previous treatments. Because these therapies rely on the patient's own immune response, there is no universal guarantee of remission. The primary goals are often to achieve progression-free survival, reduce clinical symptoms (such as pain or fatigue), and improve overall quality of life.